With durvalumab–ceralasertib, the only grade ≥3 TRAE with an incidence of ≥5% was thrombocytopenia (5.1%), while with durvalumab–olaparib anemia was reported in 13.8% of patients, and with durvalumab–danvatirsen increased alanine aminotransferase was reported in 11.1% and thrombocytopenia in 8.9% of patients (Extended Data Table 6). Here, GPT is linked to Thrombocytopenia.